Cardiac Angiosarcoma

1

Review clinical trials related to Cardiac Angiosarcoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Cardiac Angiosarcoma International Registry

Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are: 1. Collect clinical data, including demographics, medical history, treatments, and outcomes, to build a comprehensive database. 2. Analyze data to evaluate and identify genetic, environmental, or lifestyle risk factors for cardiac angiosarcoma. 3. Evaluate the effectiveness of various treatments (surgery, chemotherapy, immunotherapy, radiation) to inform best practices. 4. Develop evidence-based guidelines and recommendations for prevention, diagnosis, treatment, and management based on registry data.

Participants needed: 500
Trial details
Biological sex: AllType: ObservationalSponsor: Immune Oncology Research InstituteUpdated: Feb 18, 2026Locations: 1Duration: 5 Years
Eligibility criteria

Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through... [+6]

Patients who decline to provide informed consent. [+1]